期刊文献+

RP-HPLC法测定硼替佐米原料药中主药的含量 被引量:2

Determination of Bortezomib in Its Crude Drug by RP-HPLC
原文传递
导出
摘要 目的:建立以反相高效液相色谱法测定硼替佐米原料药中主药含量的方法。方法:色谱柱为Phenomenex-C18,流动相为甲醇-磷酸盐缓冲液(pH2.0)=60∶40,检测波长为254nm,流速为1.0mL.min-1。结果:硼替佐米检测浓度的线性范围为50.72~152.16μg·mL-1(r=0.9999);平均回收率为99.62%,RSD=0.39%(n=6)。结论:本方法灵敏度高、专属性强、操作简便,可用于该原料药的含量测定。 OBJECTIVE. To establish an RP - HPLC method for determination of the content of bortezomib in its crude drug. METHODS: Bortezomib was separated on Phenomenex- C18 chromatographic column with mobile phase consisted of methanol - phosphate buffer (pH 2.0) (60 : 40) at a flow rate of 1.0 mL · min -1.The detection wavelength was set at 254 nm. RESULTS: The linear range of bortezomib was 50.72--152.16μg (r = 0.999 9) with an average recovery rate of 99.62% (RSD = 0,39%, n = 6) . CONCLUSIONS: The method is sensitive, specific and simple in operation, and it is applicable for the determination of bortezomib in its crude drug.
出处 《中国药房》 CAS CSCD 北大核心 2009年第34期2695-2696,共2页 China Pharmacy
关键词 反相高效液相色谱法 硼替佐米 含量测定 RP - HPLC Bortezomib Content determination
  • 相关文献

参考文献2

二级参考文献9

  • 1黄灵芝.硼替佐米有望成为治疗非霍奇金淋巴瘤新药[J].国外医学(药学分册),2006,33(5):382-383. 被引量:2
  • 2Paul G, Bart Barlogie, James Berenson, et al. Extended follow-up of a phase Ⅱ trial in relapsed, refractory multiple myeloma[J].Cancer,2006,106(6):1316-1319.
  • 3Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma[J]. Blood, 2007,109(7):2767-2772.
  • 4Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival[J]. Chin Lymphoma, 2003,4 (1):32-35.
  • 5Fanucchi M P, Fossella F V, Belt R, et al. Randomized phase Ⅱ study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer [J]. J Clin Oncol,2006,24(31) :5025-5033.
  • 6Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia[J]. Cancer, 2007,109(11):2285-2290.
  • 7Kim S J, Kim J, Cho Y, et al. bortezomib, cyclophosphamide Combination chemotherapy with and dexamethasone may be effective for plasma cell leukemia[J]. Jpn J Clin Oncol, 2007, May 303 Epub ahead of print.
  • 8Yan H, Wang Y C, Li D, et al, Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta[J]. Leukemia, 2007, 21 (7) : 1488-1495.
  • 9Faderl S, Rai K, Gribben J, et al. Phase Ⅱ study of single-agent bortezomib for the treatment of patients with fludarabine- refractory B-cell chronic lymphocytic leukemia[J]. Cancer, 2006, 107(5) : 916-924.

共引文献11

同被引文献14

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部